An entirely homegrown and indigenous company, Shantha Biotechnics is the first Indian company to develop, manufacture and market a recombinant human healthcare product in India.
A pioneer in the field of biotechnology, Shantha Biotechnics is the first Indian company to develop, manufacture and market a recombinant human healthcare product in India. The company is committed to breaking new ground in modern biotechnology to address critical healthcare needs of the developing world.
Shantha is currently focusing its R&D efforts in the development of generic biologicals, novel therapeutic antibodies, proteins and vaccines. The company conducts exploratory research in the fields of oncology, infectious diseases and platform technologies.
Shanvac- B is the first Indian hepatitis-B vaccine to be pre-qualified by the WHO, Geneva, for supplying to the UN agencies globally. Today, Shantha caters to major international markets including Asia-Pacific, Africa, CIS and Latin America in addition to supra nations like UNICEF and PAHO.
Shantha has also obtained WHO pre-qualification for its combination vaccine of DPT+ hepatitis-B vaccine Shantetra, enabling supplies to the UN Agencies. Shantha is currently working on therapeutic monoclonal antibodies and pegylated proteins. The company expects to launch monoclonal antibodies by the end of this year and pegylated proteins by the middle of next year.
To make cutting edge technologies available to the common man, Shantha is constantly exploring the possibilities of partnerships to facilitate innovations in research and development. French healthcare company Merieux Alliance has about 60 percent stake in Shantha Biotechnics. Merieux bought the stake from Oman-based financial firms, which had invested in Shantha a few years ago. This alliance favors synergies in terms of research and clinical development between the group companies. Shantha Biotechnics also has access to the support provided by Merieux Alliances international network.
Shantha extends its excellent in-house expertise, core competencies and skill in development of vaccines and biologicals to carry out contract research services to its clients. Contract research is undertaken at Shantha's sprawling 50,000 sft R&D center. The center is well-equipped with the latest world class instruments and other support facilities.
Shantha has targeted infectious diseases and oncology as its primary areas of interest for conducting R&D activities. It has also taken up collaborative research with premier national and international research organizations like CCMB, IISc, Bhabha Atomic Research Center, National Institute of Immunology, Indian Institute of Chemical Biology, Jawaharlal Nehru University, International Center for Genetic Engineering and Biotechnology and National Center for Cell Sciences. A research tie-up with the International Vaccine Institute, Korea, for development and transfer of technology for various vaccines has complemented Shantha's research strengths.